ZW418 / Zymeworks - LARVOL DELTA

Development of ZW418, a biparatopic PTK7-targeting antibody-drug conjugate incorporating a novel pan-RAS inhibitor payload for the treatment of non-small cell lung cancer (AACR 2026) - "Across RAS-mutated cancer cell lines with varying PTK7 expression level, the biparatopic antibody demonstrated greater cell surface decoration, internalization, and spheroid penetration compared to cofetuzumab and other PTK7-targeted clinical benchmark antibodies. The pan-RASi ADC platform showed encouraging tolerability in mice with no significant toxicity observed up to a dose of 200 mg/kg. Overall, the data supports the potential of ZW418 as a novel, highly differentiated therapeutic agent against PTK7-expressing RAS mutant cancers."

ADC • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PTK7